Journals

I subscribe to a number of journals.

New England Journal of Medicine

Regulating Reproductive Medicine in a World without Roe
New England Journal of Medicine, Volume 388, Issue 4, Page 289-292, January 2023.
>> Read more

Sources of Innovation in Gene Therapies — Approaches to Achieving Affordable Prices
New England Journal of Medicine, Volume 388, Issue 4, Page 292-295, January 2023.
>> Read more

The Promise
New England Journal of Medicine, Volume 388, Issue 4, Page 296-297, January 2023.
>> Read more

Covid Vaccines — Playing the Long Game
New England Journal of Medicine, Volume 388, Issue 4, January 2023.
>> Read more

Heart

Heartbeat: prevention of atrial fibrillation progression
Prevention of persistent and permanent atrial fibrillation (AF) might reduce the incidence of adverse cardiovascular outcomes. Many patients initially present with paroxysmal AF and then progress to more permanent AF, yet there are few robust predictors of progressive AF. In an interim-analysis of the prospective Reappraisal of AF: Interaction Between HyperCoagulability, Electrical Remodelling, and Vascular Destabilisation in the Progression of AF (RACE V) study, the rate of AF progression was 5.5% per year.1 Multivariable predictors of progression from paroxysmal to more permanent AF were impaired left atrial function, more severe mitral regurgitation and a larger waist circumference in addition to biomarkers associated with coagulation, inflammation, cardiomyocyte stretch and atherosclerosis (figure 1). These findings suggest that risk stratification and targeted intervention to prevent progression from paroxysmal to more permanent AF may be possible. Figure 1 Predictors of atrial fibrillation (AF) progression in the Reappraisal...
>> Read more

Too much heterogeneity: envisioning a new approach to methamphetamine associated heart failure
Methamphetamine use is rising nationally,1 2 and with it the incidence of its many cardiopulmonary complications.3 Patients with cardiomyopathy and heart failure due to methamphetamine (MethHF) use are at an increased risk of acute care utilisation (eg, emergency department, inpatient hospitalisation), morbidity and mortality.4 In California, methamphetamine associated admissions increased from 1.2% of all hospitalisations in 2008 to 8% in 2018, a 600% increase.5 Methamphetamine use was an independent predictor of heart failure readmission (OR 3.62, 95% CI 1.40 to 9.38) at our safety-net hospital in San Francisco.6 Barriers to effective treatment of cardiomyopathy due to stimulant use are many: the exact pathophysiology, dose–response and incidence are unknown, continued drug use both drives further disease progression and impedes medical care engagement, and there are limited effective treatment options to reduce use. Co-occurring mental health and other substance use...
>> Read more

JACC

Heart Rhythm